Nicolas A. Parejo

1.3k total citations · 1 hit paper
22 papers, 1.0k citations indexed

About

Nicolas A. Parejo is a scholar working on Immunology, Epidemiology and Oncology. According to data from OpenAlex, Nicolas A. Parejo has authored 22 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 9 papers in Epidemiology and 5 papers in Oncology. Recurrent topics in Nicolas A. Parejo's work include Immune Response and Inflammation (18 papers), Sepsis Diagnosis and Treatment (5 papers) and Neutropenia and Cancer Infections (4 papers). Nicolas A. Parejo is often cited by papers focused on Immune Response and Inflammation (18 papers), Sepsis Diagnosis and Treatment (5 papers) and Neutropenia and Cancer Infections (4 papers). Nicolas A. Parejo collaborates with scholars based in United States, United Kingdom and Netherlands. Nicolas A. Parejo's co-authors include Steven M. Opal, John E. Palardy, John P. Pribble, Stephen F. Carroll, Jon H. Lemke, Jean‐Louis Vincent, Mark White, Patrick J. Scannon, James C. Keith and Jean Palardy and has published in prestigious journals such as Blood, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Nicolas A. Parejo

22 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock

1999 505 citations Steven M. Opal, Patrick J. Scannon et al. The Journal of Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicolas A. Parejo United States	16	477	392	218	103	87	22	1.0k
Sebastiaan Weijer Netherlands	16	444 0.9×	446 1.1×	271 1.2×	130 1.3×	55 0.6×	23	1.1k
John E. Palardy United States	20	617 1.3×	475 1.2×	342 1.6×	167 1.6×	86 1.0×	30	1.4k
Philipp M. Lepper Germany	16	486 1.0×	221 0.6×	234 1.1×	91 0.9×	70 0.8×	17	1.1k
Reuven Porat United States	16	601 1.3×	250 0.6×	291 1.3×	82 0.8×	55 0.6×	26	1.2k
C V Keogh United States	10	554 1.2×	515 1.3×	174 0.8×	144 1.4×	96 1.1×	16	1.2k
Catherine Valentine United States	9	679 1.4×	431 1.1×	372 1.7×	125 1.2×	57 0.7×	9	1.4k
M. P. Glauser Switzerland	18	618 1.3×	384 1.0×	208 1.0×	103 1.0×	106 1.2×	33	1.3k
S M Opal United States	9	292 0.6×	332 0.8×	185 0.8×	65 0.6×	64 0.7×	11	912
Malte Book Germany	19	286 0.6×	429 1.1×	176 0.8×	108 1.0×	117 1.3×	41	983
William Lynn United Kingdom	12	438 0.9×	244 0.6×	145 0.7×	76 0.7×	81 0.9×	43	983

Countries citing papers authored by Nicolas A. Parejo

Since Specialization

Citations

This map shows the geographic impact of Nicolas A. Parejo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas A. Parejo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas A. Parejo more than expected).

Fields of papers citing papers by Nicolas A. Parejo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas A. Parejo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas A. Parejo. The network helps show where Nicolas A. Parejo may publish in the future.

Co-authorship network of co-authors of Nicolas A. Parejo

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas A. Parejo. A scholar is included among the top collaborators of Nicolas A. Parejo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas A. Parejo. Nicolas A. Parejo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ramachandran, Girish, Raymond Kaempfer, Chun‐Shiang Chung, et al.. (2014). CD28 Homodimer Interface Mimetic Peptide Acts as a Preventive and Therapeutic Agent in Models of Severe Bacterial Sepsis and Gram-Negative Bacterial Peritonitis. The Journal of Infectious Diseases. 211(6). 995–1003. 30 indexed citations

Christaki, Eirini, Steven M. Opal, James C. Keith, et al.. (2011). A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia. Shock. 35(5). 492–498. 44 indexed citations

Opal, Steven M., Yow‐Pin Lim, Patricia Cristofaro, et al.. (2010). Inter-α Inhibitor Proteins. Shock. 35(1). 42–44. 28 indexed citations

Christaki, Eirini, Steven M. Opal, James C. Keith, et al.. (2010). Estrogen Receptor β Agonism Increases Survival in Experimentally Induced Sepsis and Ameliorates the Genomic Sepsis Signature: A Pharmacogenomic Study. The Journal of Infectious Diseases. 201(8). 1250–1257. 36 indexed citations

Cristofaro, Patricia, Steven M. Opal, John E. Palardy, et al.. (2006). WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Critical Care Medicine. 34(8). 2188–2193. 49 indexed citations

Opal, Steven M., John E. Palardy, Patricia Cristofaro, et al.. (2005). THE ACTIVITY OF PATHWAY-SELECTIVE ESTROGEN RECEPTOR LIGANDS IN EXPERIMENTAL SEPTIC SHOCK. Shock. 24(6). 535–540. 7 indexed citations

Opal, Steven M., John E. Palardy, Wilbur H. Chen, et al.. (2005). Active Immunization with a Detoxified Endotoxin Vaccine Protects against Lethal Polymicrobial Sepsis: Its Use with CpG Adjuvant and Potential Mechanisms. The Journal of Infectious Diseases. 192(12). 2074–2080. 26 indexed citations

Artenstein, Andrew W., Steven M. Opal, Patricia Cristofaro, et al.. (2004). Chloroquine Enhances Survival inBacillusanthracisIntoxication. The Journal of Infectious Diseases. 190(9). 1655–1660. 25 indexed citations

Opal, Steven M., et al.. (2003). Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Critical Care Medicine. 31(3). 929–932. 24 indexed citations

10.

Opal, Steven M., et al.. (2002). Orally Administered Recombinant Human Interleukin‐11 Is Protective in Experimental Neutropenic Sepsis. The Journal of Infectious Diseases. 187(1). 70–76. 21 indexed citations

11.

Opal, Steven M., et al.. (2001). EVALUATION OF THE SAFETY OF RECOMBINANT P-SELECTIN GLYCOPROTEIN LIGAND-IMMUNOGLOBULIN G FUSION PROTEIN IN EXPERIMENTAL MODELS OF LOCALIZED AND SYSTEMIC INFECTION. Shock. 15(4). 285–290. 13 indexed citations

12.

Opal, Steven M., John E. Palardy, Nicolas A. Parejo, & David C. Morrison. (2001). Lipopolyamines as a therapeutic strategy in experimental Gram-negative bacterial sepsis. Journal of Endotoxin Research. 7(1). 35–38. 1 indexed citations

13.

Opal, Steven M., et al.. (2001). Active Immunization with a DetoxifiedEscherichia coliJ5 Lipopolysaccharide Group B Meningococcal Outer Membrane Protein Complex Vaccine Protects Animals from Experimental Sepsis. The Journal of Infectious Diseases. 183(7). 1079–1086. 38 indexed citations

14.

Simpson, Andrew J. H., Steven M. Opal, Brian Angus, et al.. (2000). Differential Antibiotic‐Induced Endotoxin Release in Severe Melioidosis. The Journal of Infectious Diseases. 181(3). 1014–1019. 55 indexed citations

15.

Opal, Steven M., James C. Keith, John E. Palardy, & Nicolas A. Parejo. (2000). Recombinant Human Interleukin‐11 Has Anti‐inflammatory Actions Yet Does Not Exacerbate SystemicListeriaInfection. The Journal of Infectious Diseases. 181(2). 754–756. 12 indexed citations

16.

Opal, Steven M., Patrick J. Scannon, Jean‐Louis Vincent, et al.. (1999). Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock. The Journal of Infectious Diseases. 180(5). 1584–1589. 505 indexed citations breakdown →

17.

Opal, Steven M., Jhung W. Jhung, James C. Keith, et al.. (1998). Recombinant Human Interleukin‐11 in ExperimentalPseudomonas aeruginosaSepsis in Immunocompromised Animals. The Journal of Infectious Diseases. 178(4). 1205–1208. 30 indexed citations

18.

Opal, Steven M., et al.. (1996). Potentia Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock. The Journal of Infectious Diseases. 173(6). 1415–1421. 42 indexed citations

19.

Opal, Steven M., et al.. (1996). The in vivo significance of antibiotic-induced endotoxin release in experimental Gram-negative sepsis. Journal of Endotoxin Research. 3(3). 245–252. 16 indexed citations

20.

Opal, Steven M., et al.. (1995). Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis. Antimicrobial Agents and Chemotherapy. 39(12). 2813–2815. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact